Vaxart To Meet With FDA In Mid-2024 To Evaluate Clinical Data And Discuss Next Steps For Its Norovirus Program; Anticipates Cash Runway Into Late Q4 Of 2024
Portfolio Pulse from Benzinga Newsdesk
Vaxart plans to meet with the FDA in mid-2024 to discuss the clinical data and future steps for its Norovirus program, with expectations to extend its cash runway into late Q4 of 2024. The company also plans to initiate a Phase 2b study for its oral XBB COVID-19 vaccine in Q2 of 2024. As of March 31, 2024, Vaxart's financials include $36.7 million in cash, cash equivalents, and investments.

May 13, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxart's upcoming FDA meeting and plans for a Phase 2b study of its COVID-19 vaccine could positively impact investor sentiment, supported by a solid cash position into late 2024.
The announcement of a planned FDA meeting for Vaxart's Norovirus program and the initiation of a Phase 2b study for its COVID-19 vaccine are significant positive developments. These steps indicate progress in its pipeline and could enhance investor confidence, especially with the company's reported cash runway extending into late 2024. The financial stability and ongoing clinical advancements are likely to be viewed positively by the market, potentially leading to an uptick in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100